The UK aesthetic clinic intelligence platform.
Proprietary clinic data, AI-powered enrichment, and continuous monitoring. Purpose-built for the companies that sell into the UK aesthetic ecosystem.
A continuous stream of market intelligence, built from dozens of live trackers, augmented with public records, and verified directly by clinic owners themselves.
Every record is assembled from multiple independent sources. Continuously updated, cross-validated, and audit-traced. The dataset grows deeper every day.
Three workflows. One dataset. Every decision in UK aesthetics.
Commercial, regulatory, and investment teams use KalliData to answer the questions that move the needle, without the weeks of manual research it would otherwise take.
Find the right clinics
Segment the UK aesthetic market by geography, treatment offering, practitioner qualification, brand affiliation, or commercial maturity. Ship prioritised lists straight to your CRM.
Monitor the market in motion
Continuous tracking of pricing, treatment mix, brand adoption and category trends across 15,000 clinics. Spot movement before competitors do.
Stay compliant, stay confident
Cross-reference practitioner credentials, licensing status, and regulatory signals. Meet your pharmacovigilance obligations and protect brand integrity under the 2027 licensing regime.
Built for the companies that sell into UK aesthetics.
One dataset, tailored to how each industry buys, targets, and measures success.
Pharma & Injectables
Sales targeting, brand visibility, prescriber verification, and pharmacovigilance for botulinum toxin, dermal fillers, and biostimulators.
Professional Beauty & Skincare
Territory planning, account prioritisation, and competitor brand tracking for cosmeceutical skincare sold through clinics.
Investors & Corporate Finance
Market sizing, white-space mapping, buy-and-build target lists, and portfolio monitoring for PE, VC, M&A and healthcare lenders.
If you've asked any of these, KalliData was built for you.
Every commercial, regulatory, and investment decision in UK aesthetics starts with a question about clinics, practitioners, or brands.
Market data. Regulatory commentary. Methodology.
GLP-1 adoption in UK aesthetics — H1 2026
22% of London skin clinics now offer Wegovy, Mounjaro, or Ozempic — up from 8% a year ago. The trajectory, the regional pattern, and the implications for injectable pharma.
The UK licensing regime: 2027 readiness report
What the amber and green tiers mean for 15,000 UK clinics. Regional rollout timeline and estimated impact on supplier sales motion.
How we verify practitioner credentials
GMC / NMC cross-referencing, Save Face accreditation, and JCCP registration. Why clinic-level data alone isn't enough.
See your territory, your competitors, or your target list. In 20 minutes.
Every demo is tailored. Tell us your market, your product, or your investment thesis. We'll show you what the platform sees.